Lophius Biosciences closes €1.4m additional financing
5 August 2011
Lophius Biosciences, a developer of novel, innovative
T-cell-based diagnostic test systems, has announced the closing of an
additional financing round totaling €1.4 million.
All its current
financial investors, such as S-Refit, High-Tech Gründerfonds (HTGF)
and Bayernkapital participated. The
funds will be used for the market introduction of the T-Track CMV/EBV
tests in the field of transplantation, for further development of a
diagnostic test for the differential diagnosis of tuberculosis, as
well as for the new development of a novel, blood-based multiple
sclerosis test.
“We are very pleased to have been able to conclude this financing
round with our existing investors in such a short time. Subsequent to
the successful establishment of the company over the past year and the
imminent conclusion of the test developments for our patented T-Track CMV/EBV Tests, these new financial resources allow us to prepare for
market entry of these tests from the beginning of 2012 with an effective
team. Beyond this, we will now intensify the development of additional
innovative diagnostic tests based on our patented technology platforms,”
said Dr. Michael Lutz, CEO of Lophius Biosciences.
“With the aid of the financing round in the precious year Lophius
Biosciences has been able to develop from an essentially academic
research company into a small, highly innovative and fully integrated
diagnostic company within a very short timeframe. We are absolutely
convinced that the Lophius’ technologies and the products have a great
potential to provide patients with large diagnostic benefits in our
disease areas,” amended Bertram Gilka-Bötzow of S-Refit, Lophius
Biosciences’ lead investor.
Source: Lophius Biosciences